Beta‐blockers in portal hypertension: new developments and controversies

Tripathi, Dhiraj; Hayes, Peter

doi:10.1111/liv.12360

Cited by 50 publications

(44 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Non-selective beta-blockers such as propranolol are the only drugs used in clinics to treat portal hypertension; however, only a third to half of patients have a satisfactory reduction in portal pressure after treatment [2]. Surgeries to alleviate portal hypertension are usually limited by their disadvantages or by the physical condition of the patient.…”

Section: Introductionmentioning

confidence: 98%

Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats

Wang

Yin

Dong

et al. 2015

Digestive and Liver Disease

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats

Wang

Yin

Dong

et al. 2015

Digestive and Liver Disease

View full text Add to dashboard Cite

“…Up to now, only nonselective betablockers (NSBBs) such as propranolol are the only drugs recommended in the treatment of PHT. The most important hemodynamic effect of NSBBs is a decrease in cardiac output via β 1 receptors and a splanchnic vasoconstriction through β 2 receptors, leading to a reduction in portal inflow . However, only a third to half of patients have a satisfactory hemodynamic response to NSBB treatment.…”

Section: Introductionmentioning

confidence: 99%

Combined administration of propranolol + AG490 offers better effects on portal hypertensive rats with cirrhosis

Wang

Yin

et al. 2016

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…However, there are safety issues on the use of NSBBs in patients with cirrhosis and refractory ascites [31,32] . In a 0.85, 95%CI: 0.53-1.39].…”

Section: Nsbbs Vs No Interventionmentioning

confidence: 99%

Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis

Triantos

Kalafateli

2014

WJH

View full text Add to dashboard Cite

Variceal bleeding is a life threatening situation with mortality rates of at least 20%. Prophylactic treatment with non-selective beta blockers (NSBBs) is recommended for patients with small varices that have not bled but with increased risk for bleeding. The recommended treatment strategies on primary prevention of variceal bleeding in patients with medium and largesized varices are NSBBs or endoscopic band ligation. Nitrates, shunt surgery and sclerotherapy are not recommended in this setting. In this review, the most recent data on prevention of esophageal variceal bleeding are presented. Available data derived from randomized-controlled trials suggest both treatment strategies, and according to Baveno V consensus in portal hypertension "the choice of treatment should be based on local resources and expertise, patient preference and characteristics, side-effects and contra-indications". Core tip: The significance of primary prevention of bleeding from esophageal varices in patients with liver cirrhosis is major, considering the high mortality rates that accompany the acute bleeding episode. Current management guidelines suggest the use of either nonselective beta-blockers or endoscopic band ligation with same efficacy between them. In this review, we summarize data from randomized clinical trials or prospective studies together with meta-analytical data, when applicable, to present the most updated recommendations on primary prevention of esophageal variceal bleeding.Triantos C, Kalafateli M. Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis.

show abstract

Beta‐blockers in portal hypertension: new developments and controversies

Abstract: There are many studies investigating the role of non-selective beta-blockers in portal hypertension.

Cited by 50 publications

References 97 publications

Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats

Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats

Combined administration of propranolol + AG490 offers better effects on portal hypertensive rats with cirrhosis

Primary prevention of bleeding from esophageal varices in patients with liver cirrhosis

Contact Info

Product

Resources

About